查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010933

卵巢癌治療市場：2026-2032年全球市場預測（按癌症類型、治療方法、藥物分類、給藥途徑、分銷管道和最終用戶分類）

Ovarian Cancer Drugs Market by Cancer Type, Treatment Type, Therapeutic Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，卵巢癌治療市場價值將達到 51.3 億美元，到 2026 年將成長至 58 億美元，到 2032 年將達到 129.4 億美元，複合年成長率為 14.12%。

主要市場統計數據
基準年 2025 51.3億美元
預計年份：2026年 58億美元
預測年份 2032 129.4億美元
複合年成長率 (%) 14.12%

對重塑卵巢癌治療路徑和相關人員優先事項的系統性因素進行了清晰的概述，包括治療和診斷技術的進步。

卵巢癌治療已進入一個變革時期，這主要得益於標靶治療、免疫腫瘤學和最佳化化療方案的進步。本文將全面概述治療方法，重點關注臨床進展、監管變化以及影響研究、臨床實踐和商業整體情況決策的許多因素。

詳細分析精準醫療、適應性臨床試驗設計和不斷發展的支付方框架如何重新定義卵巢癌治療的採用和發展策略。

卵巢癌的治療格局正在經歷一場變革，這主要得益於分子水平表徵的進步、標靶治療日益成長的關注，這些聯合治療旨在擴大臨床獲益。精準醫學的進步使得利用實用生物標記對患者進行分層成為可能，從而提高了標靶DNA修復缺陷和血管生成通路藥物的臨床效用。這促使人們更加關注開發治療方法直接影響腫瘤生物學特性或增強免疫介導的腫瘤控制的治療方法。

對 2025 年價格趨勢將如何重塑整個卵巢癌治療價值鏈的供應鏈、採購行為和策略性成本降低方法進行嚴格評估。

美國2025年實施的新關稅措施，為癌症治療領域的製藥企業和經銷商的供應鏈規劃和成本管理帶來了新的複雜性。與關稅相關的原料藥、關鍵原料和成品藥進口成本基礎的調整，可能在採購、生產和分銷的各個環節造成壓力。這促使製造商重新評估其供應商佈局，考慮將關鍵零件的生產轉移到國內或附近地區，並尋求更高的垂直整合度，以降低關稅波動帶來的風險。

基於全面細分的洞察，將疾病亞型、治療機制、給藥途徑、分銷管道和醫療保健環境與策略研發和商業化選擇聯繫起來。

對卵巢癌治療市場進行精細細分，揭示了不同疾病亞型、治療方法、給藥機制、分銷管道和醫療機構在臨床和商業性趨勢上的差異。以癌症類型分類，本檢驗了上皮性卵巢癌、生殖細胞腫瘤、小細胞卵巢癌和間質細胞腫瘤的市場模式。每種癌症都具有獨特的生物學特徵、診斷挑戰和治療反應，這些都會影響研發重點和臨床試驗設計。按治療方法，本分析涵蓋了化療、荷爾蒙療法、免疫療法、放射線治療和標靶治療，並重點關注聯合治療和治療順序策略如何最佳化患者療效和提高商業性可行性。

從策略區域分析的角度解釋主要全球區域的監管、支付方和臨床基礎設施特徵如何影響開發和准入策略。

區域趨勢顯著影響卵巢癌治療藥物的研發重點、監管策略和商業化路徑。在美洲，臨床試驗能力、支付方的專業知識以及成熟的腫瘤學網路，共同創造了一個有利於新藥快速推廣的環境，而這些新藥的推廣是基於可靠的臨床療效和成本效益證據。儘管該地區與監管機構的互動往往側重於明確的臨床終點和全面的安全性評估，但與支付方的談判通常側重於基於療效的條件以及提供額外數據等方面的協議。

詳細的公司趨勢顯示，成熟公司、生物技術創新者、契約製造製造商和診斷合作夥伴正在調整其策略，以推進卵巢癌治療的發展。

卵巢癌治療領域的公司層面趨勢反映出，成熟的跨國製藥公司、靈活的生物技術創新者、契約製造組織和專業診斷服務提供者之間存在著持續性。大型製藥企業通常會利用其豐富的臨床開發資源、與全球監管機構談判的經驗以及廣泛的商業網路來支持後期研發項目和聯合治療。它們的優先事項通常包括生命週期管理以保持競爭優勢、拓展適應症以及整合伴隨診斷。

決策者面臨的可操作的策略挑戰是，如何協調臨床差異化、供應彈性和支付方參與，以實現永續的市場進入和推廣。

產業領導者應優先考慮整合臨床開發、供應鏈韌性和支付方合作的綜合方法，以確保並擴大卵巢癌治療的可及性。早期投資生物標記計畫和伴隨診斷可提高在目標族群中證實具有臨床意義的益處的可能性，並有助於獲得更有利的報銷談判結果。同時，將真實世界證據的收集納入核准後計劃，可增強價值主張，並在適當情況下支持基於結果的合約。

透明且可重複的研究途徑，結合文獻綜述、專家訪談和交叉檢驗，確保了可靠的臨床和商業性結果。

本執行摘要的調查方法結合了系統性的證據整合、定性專家對話以及對公開臨床和監管資訊的三角檢驗。主要資訊來源包括同儕審查的臨床文獻、監管申報文件、臨床試驗註冊資訊以及來自重要腫瘤學會議的結果數據。除上述資訊來源外，我們還對臨床研究人員、醫保報銷專家和商業領域領導者進行了結構化訪談，以確定實施過程中的實際考慮、准入障礙和市場趨勢。

簡明扼要地整合了治療方法進展、獲取挑戰以及為在整個醫療保健系統中實現臨床獲益和永續獲取所需的協作努力。

總之，卵巢癌治療生態系在取得重大科學進展的同時，也面臨著巨大的商業性和營運複雜性。標靶治療、免疫腫瘤學方法和診斷技術的進步為改善患者預後創造了機遇，但這些機會受到支付方預期、供應鏈現實以及區域間醫療資源分配不均等因素的限制。能夠將臨床開發與切實可行的准入計劃和穩健的生產策略相結合的相關人員，將更有能力將創新轉化為永續的患者獲益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以癌症類型分類的卵巢癌治療市場

  • 上皮性卵巢癌
  • 生殖細胞腫瘤
  • 小細胞卵巢癌
  • 間質瘤

第9章：依治療方法分類的卵巢癌治療市場

  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 放射線治療
  • 分子標靶治療

第10章：依療法分類分類的卵巢癌治療市場

  • 血管新生抑制劑
  • PARP抑制劑
  • PD-L1抑制劑

第11章卵巢癌治療藥物市場：依給藥途徑分類

  • 靜脈注射
  • 口服

第12章卵巢癌治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章卵巢癌治療藥物市場：依最終用戶分類

  • 癌症中心
  • 診所
  • 醫院

第14章卵巢癌治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章卵巢癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章卵巢癌治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國卵巢癌治療市場

第18章：中國卵巢癌治療藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Aravive, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Compugen Ltd.
  • GlaxoSmithKline plc
  • ImmunoGen, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Oncxerna Therapeutics, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sutro Biopharma, Inc.
  • Tesaro, Inc.
  • Zentalis Pharmaceuticals, Inc.
Product Code: MRR-434CCDA052A2

The Ovarian Cancer Drugs Market was valued at USD 5.13 billion in 2025 and is projected to grow to USD 5.80 billion in 2026, with a CAGR of 14.12%, reaching USD 12.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.13 billion
Estimated Year [2026] USD 5.80 billion
Forecast Year [2032] USD 12.94 billion
CAGR (%) 14.12%

A clear contextual overview of therapeutic progress, diagnostic advances, and systemic forces reshaping ovarian cancer treatment pathways and stakeholder priorities

The management of ovarian cancer has entered an era of substantive therapeutic evolution, with advances spanning targeted therapies, immuno-oncology, and optimized chemotherapeutic regimens. This introduction frames the current therapeutic landscape by emphasizing clinical progress, regulatory shifts, and the broader drivers shaping decision-making across research, clinical practice, and commercial strategy.

Emerging biologics, precision-targeted agents, and evolving standards of care have redefined clinical pathways for many ovarian cancer subtypes. Concurrently, improvements in diagnostic sensitivity, biomarker stratification, and combination regimen design have elevated the expectations for patient outcomes. As stakeholders contend with a complex interplay of innovation, access, and affordability, understanding these dynamics is essential for effective portfolio prioritization and resource allocation.

This section lays the groundwork for the deeper analysis that follows, focusing on how clinical advances intersect with payer dynamics, supply chain considerations, and evolving patient-centric models of care. By establishing this context, readers are positioned to interpret subsequent insights on competitive shifts, segmentation-level nuances, and region-specific implications with greater clarity and strategic relevance.

An in-depth exploration of how precision medicine, adaptive clinical design, and evolving payer frameworks are redefining adoption and development strategies in ovarian cancer therapeutics

The ovarian cancer drug landscape is experiencing transformative shifts driven by improved molecular characterization, the maturation of targeted modalities, and a growing emphasis on combination strategies that extend clinical benefit. Precision medicine advances have enabled the stratification of patients by actionable biomarkers, thereby increasing the clinical utility of agents designed to exploit DNA repair deficiencies and angiogenesis pathways. This has led to an accelerated focus on developing therapies that either directly target tumor biology or enhance immune-mediated tumor control.

Parallel to therapeutic innovation, trial design has evolved to incorporate adaptive protocols, biomarker-enriched cohorts, and surrogate endpoints that expedite evaluation without compromising scientific rigor. Regulatory agencies are increasingly open to expedited pathways for agents that demonstrate meaningful clinical improvement in well-defined populations, which in turn is changing sponsor development strategies and commercialization timelines.

Commercially, payers and providers are responding to these clinical shifts with more nuanced coverage approaches that emphasize value-based contracting, real-world evidence generation, and outcomes-based agreements. In practice, this has incentivized manufacturers to invest in post-approval studies, health economics and outcomes research, and stakeholder engagement programs to support formulary access. Taken together, these shifts are not only altering the therapeutic arsenal available to clinicians but also redefining how success is measured and how therapies are adopted within health systems.

A rigorous assessment of how 2025 tariff dynamics are reshaping supply chains, procurement behavior, and strategic cost mitigation approaches across the ovarian cancer therapeutic value chain

The introduction of new tariff measures in the United States in 2025 has injected fresh complexity into supply chain planning and cost management for pharmaceutical manufacturers and distributors involved in oncology therapeutics. Tariff-related adjustments to the cost base of active pharmaceutical ingredients, critical raw materials, and finished drug imports can create pressure points across procurement, manufacturing, and distribution. This has prompted manufacturers to re-evaluate supplier footprints, to consider onshoring or nearshoring of key components, and to explore greater vertical integration to mitigate exposure to tariff volatility.

For healthcare providers and payers, tariff-driven cost shifts translate into potential changes in procurement strategies and formulary negotiations. Hospitals and cancer centers may respond by optimizing inventory management, prioritizing therapeutics with more secure supply chains, and engaging in multi-year purchasing agreements to lock in pricing. Simultaneously, manufacturers face increased scrutiny to demonstrate value through clinical differentiation or service offerings that justify any upward pressure on net prices.

From a strategic vantage, organizations that proactively model tariff scenarios, diversify supplier networks, and incorporate contingency clauses into contracts will be better positioned to sustain continuity of care. Moreover, real-world evidence and pharmacoeconomic data become even more critical levers when justifying access decisions in an environment of heightened cost transparency and supply uncertainty. Ultimately, the cumulative impact of tariffs is less about a single cost increase and more about how it reshapes strategic priorities across R&D sourcing, manufacturing location decisions, and commercial access tactics.

Comprehensive segmentation-driven insights linking disease subtypes, therapeutic mechanisms, administration routes, distribution channels, and care settings to strategic R&D and commercialization choices

A nuanced segmentation of the ovarian cancer therapeutics market reveals differentiated clinical and commercial dynamics across disease subtype, treatment modality, therapeutic mechanism, mode of administration, distribution route, and care setting. Based on Cancer Type, the landscape is examined across Epithelial Ovarian Cancer, Germ Cell Tumors, Small Cell Ovarian Cancer, and Stromal Cell Tumors, each presenting unique biological characteristics, diagnostic challenges, and therapeutic responsiveness that influence development priorities and clinical trial designs. Based on Treatment Type, analyses explore Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, and Targeted Therapy, with specific attention to where combination regimens or sequencing strategies can optimize patient outcomes and commercial viability.

Based on Therapeutic Class, the review details Angiogenesis Inhibitors, PARP Inhibitors, and PD-L1 Inhibitors, highlighting distinct mechanisms of action, biomarker dependencies, and resistance pathways that shape clinical utility. Based on Route Of Administration, contrasts between Intravenous and Oral delivery are explored, including implications for adherence, outpatient care utilization, and cost components associated with administration. Based on Distribution Channel, insights consider Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy dynamics, with an emphasis on how channel mix affects patient access, reimbursement pathways, and logistics. Based on End User, the report evaluates Cancer Centers, Clinics, and Hospitals, recognizing differences in treatment protocols, procurement capabilities, and capacity to deliver complex regimens.

Interpreting these segmentation lenses in concert reveals where incremental innovation, improved diagnostics, or delivery optimization can most substantially influence outcomes and adoption. For stakeholders, segmentation clarity supports targeted development plans, differentiated go-to-market strategies, and more precise health economics evidence generation tailored to the needs of distinct patient cohorts and care settings.

A strategic regional analysis describing how distinct regulatory, payer, and clinical infrastructure characteristics in major global regions affect development and access strategies

Regional dynamics exert a profound influence on development priorities, regulatory strategy, and commercialization pathways for ovarian cancer therapeutics. In the Americas, clinical trial capacity, payer sophistication, and established oncology networks create an environment conducive to rapid uptake of novel agents, contingent on robust evidence of clinical benefit and cost-effectiveness. Regulatory interactions in this region tend to favor clear clinical endpoints and comprehensive safety profiling, while payer negotiations frequently center on outcomes-based terms and supplemental data commitments.

In Europe, Middle East & Africa, diversity in regulatory frameworks and payer systems necessitates tailored market access plans that account for national HTA processes, varying reimbursement thresholds, and heterogeneity in clinical infrastructure. Countries within this region can move at different paces; therefore, parallel regulatory strategies and phased dossier submissions are common approaches to optimize launch sequencing and resource allocation.

In Asia-Pacific, high-growth healthcare investments, expanding clinical trial ecosystems, and increasing domestic manufacturing capabilities are key market drivers. Regulatory harmonization efforts and accelerating approvals for oncology indications in several APAC jurisdictions have created opportunities for earlier entry, particularly when local evidence generation or bridging studies support regional applicability. Each region's infrastructure, reimbursement mechanisms, and patient pathway nuances must be integrated into a comprehensive go-to-market strategy to ensure clinical adoption and sustainable access.

Detailed corporate insights illustrating how incumbents, biotech innovators, contract manufacturers, and diagnostics partners are aligning strategies to advance ovarian cancer therapies

Company-level dynamics in the ovarian cancer therapeutics arena reflect a continuum between established multinational pharmaceutical firms, nimble biotechnology innovators, contract manufacturing organizations, and specialized diagnostics providers. Large pharmaceutical companies typically leverage broad clinical development resources, global regulatory experience, and extensive commercial networks to support late-stage assets and combination regimens. Their priorities often include lifecycle management, label expansions, and the integration of companion diagnostics to sustain competitive advantage.

Biotechnology firms and clinical-stage innovators frequently focus on mechanism-driven differentiation, early biomarker validation, and strategic partnerships that enable accelerated pathways to market. These entities are also more likely to engage in alliance-based approaches, leveraging co-development, licensing, or co-commercialization agreements to scale clinical programs and de-risk late-stage investment. Contract and specialty manufacturers play a critical role in ensuring supply continuity, addressing capacity constraints, and supporting formulation innovation that may enable more convenient routes of administration.

Diagnostics companies and digital health vendors contribute critical capabilities for patient selection, monitoring, and real-world evidence generation. Their tools enhance trial efficiency and support post-approval evidence needs that are increasingly demanded by regulators and payers. Overall, company strategy is converging toward collaborative models that align therapeutic innovation with diagnostic precision and commercial agility to address the multifaceted challenges of advancing ovarian cancer care.

Actionable strategic imperatives for decision-makers to harmonize clinical differentiation, supply resilience, and payer engagement for durable market access and uptake

Industry leaders should prioritize an integrated approach that aligns clinical development, supply chain resilience, and payer engagement to secure and expand access for ovarian cancer therapeutics. Early investment in biomarker programs and companion diagnostic development will increase the probability of demonstrating clinically meaningful benefit in targeted populations and will facilitate more favorable reimbursement discussions. Simultaneously, embedding real-world evidence generation into post-approval plans will reinforce value arguments and support performance-based contracting where appropriate.

From an operational perspective, diversifying supplier networks and exploring regional manufacturing options can mitigate tariff and geopolitical risks while shortening lead times and improving responsiveness to demand fluctuations. Commercially, developing differentiated service offerings-such as adherence support, patient navigation, and comprehensive data dashboards for clinicians and payers-can strengthen product positioning beyond clinical efficacy alone. Finally, forging strategic alliances with diagnostics providers, health systems, and patient advocacy groups will help to accelerate adoption, inform clinical guidelines, and ensure that treatment pathways reflect both efficacy and patient-centered outcomes.

A transparent and replicable research approach integrating literature synthesis, expert interviews, and cross-validation to ensure robust clinical and commercial insights

The research methodology underpinning this executive summary combines systematic evidence synthesis, qualitative expert engagement, and triangulation of publicly available clinical and regulatory information. Primary inputs include peer-reviewed clinical literature, regulatory filings, trial registries, and outcome data from recognized oncology conferences. These sources are complemented by structured interviews with clinical investigators, reimbursement specialists, and commercial leaders to surface practical considerations around adoption, barriers to access, and landscape dynamics.

Analytical processes involve mapping therapeutic mechanisms to clinical endpoints, assessing the implications of administration routes and distribution channels on adoption, and evaluating payer and provider decision drivers across regions. Validation steps include cross-referencing trial outcomes with regulatory decisions and consulting clinical experts to ensure interpretive accuracy. Where gaps exist, targeted follow-up interviews and scenario modeling are employed to clarify likely operational and strategic impacts, ensuring that conclusions are robust, actionable, and clinically grounded.

A concise synthesis of therapeutic advancements, access challenges, and collaborative actions required to realize clinical benefit and sustainable access across healthcare systems

In conclusion, the ovarian cancer therapeutic ecosystem is characterized by meaningful scientific progress alongside material commercial and operational complexity. Advances in targeted therapies, immuno-oncology approaches, and diagnostics have created opportunities to improve patient outcomes, yet those opportunities are mediated by payer expectations, supply chain realities, and regional heterogeneity in access infrastructure. Stakeholders that align clinical development with pragmatic access planning and resilient manufacturing strategies will be best positioned to translate innovation into sustained patient benefit.

As the landscape continues to evolve, integrating real-world evidence, prioritizing biomarker-driven trials, and constructing flexible commercial models will be indispensable. The collective momentum toward more personalized and value-driven care offers a pathway to both improved clinical outcomes and optimized resource utilization, provided that sponsors, providers, and payers collaborate effectively to navigate the intricate interface between clinical promise and system-level feasibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ovarian Cancer Drugs Market, by Cancer Type

  • 8.1. Epithelial Ovarian Cancer
  • 8.2. Germ Cell Tumors
  • 8.3. Small Cell Ovarian Cancer
  • 8.4. Stromal Cell Tumors

9. Ovarian Cancer Drugs Market, by Treatment Type

  • 9.1. Chemotherapy
  • 9.2. Hormonal Therapy
  • 9.3. Immunotherapy
  • 9.4. Radiation Therapy
  • 9.5. Targeted Therapy

10. Ovarian Cancer Drugs Market, by Therapeutic Class

  • 10.1. Angiogenesis Inhibitors
  • 10.2. PARP Inhibitors
  • 10.3. PD-L1 Inhibitors

11. Ovarian Cancer Drugs Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Ovarian Cancer Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Ovarian Cancer Drugs Market, by End User

  • 13.1. Cancer Centers
  • 13.2. Clinics
  • 13.3. Hospitals

14. Ovarian Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Ovarian Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Ovarian Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Ovarian Cancer Drugs Market

18. China Ovarian Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. Aravive, Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. Clovis Oncology, Inc.
  • 19.10. Compugen Ltd.
  • 19.11. GlaxoSmithKline plc
  • 19.12. ImmunoGen, Inc.
  • 19.13. Johnson & Johnson
  • 19.14. Merck & Co., Inc.
  • 19.15. Mersana Therapeutics, Inc.
  • 19.16. Novartis AG
  • 19.17. Oncxerna Therapeutics, Inc.
  • 19.18. Pfizer Inc.
  • 19.19. Regeneron Pharmaceuticals, Inc.
  • 19.20. Roche Holding AG
  • 19.21. Sutro Biopharma, Inc.
  • 19.22. Tesaro, Inc.
  • 19.23. Zentalis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GERM CELL TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GERM CELL TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GERM CELL TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY SMALL CELL OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY SMALL CELL OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY SMALL CELL OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY STROMAL CELL TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY STROMAL CELL TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY STROMAL CELL TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)